Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19343832 | 0.86 | ABL1 (0.56) | — | |
| SCHEMBL25004 | 0.86 | ABL1 (0.56) | — | |
| SCHEMBL19344406 | 0.86 | PRMT6 (0.43) | ADORA3PRMT6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19146448 | 0.85 | CYP1A2 (0.48) | PRMT6NPC1RAB9ASMN1; SMN2P2RY12 | |
| SCHEMBL19146239 | 0.85 | P2RY12 (0.44) | ADORA3PRMT6P2RY12 | |
| SCHEMBL31093228 | 0.84 | SLC29A1 (0.49) | ADORA3NPC1RAB9ASMN1; SMN2ADORA1 | |
| SCHEMBL26455122 | 0.84 | ADORA3 (0.45) | ADORA3PRMT6P2RY12 | |
| SCHEMBL26455308 | 0.84 | ADORA3 (0.45) | ADORA3PRMT6P2RY12 | |
| SCHEMBL26455293 | 0.84 | ADORA3 (0.45) | ADORA3PRMT6P2RY12 | |
| SCHEMBL14968142 | 0.83 | PRMT6 (0.41) | ADORA3PRMT6BMPR1BP2RY12ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601313-B1 | MODIFIED CYCLIC DINUCLEOTIDE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-10 | — | — | EP | disclosed |
| WO-2019046498-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |